Approval Delays For Transcept's Insomnia Drug Come At A Price; Milestone Payments At Stake
This article was originally published in The Pink Sheet Daily
Executive Summary
Transcept expects Purdue to pay a significantly lower approval milestone payment for Intermezzo given regulatory delays.
You may also be interested in...
Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data
FDA approved a resubmission plan that responds to concerns about inadvertent re-dosing and next-day driving impairment raised in an October "complete response" letter.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.